Genome editing with #CRISPR is the most important life science breakthrough of our time. It's a B.C. and A.C. We interviewed @WalterIsaacson about his new book, THE CODE BREAKER, which is a masterpiece medscape.com/viewarticle/95…
w/ transcript /1
We started the conversation reading 2 key passages that convey the significance of #CRISPR /2
And this one /3
The book is not just about @doudna_lab and other protagonists, such as @zhangf@geochurch@EricLander46, Emmanuelle Charpentier, but thru the perspective of grad students and post docs and about team science /4
There is substantial emphasis on the power of basic science, curiosity and creativity, and not just the linear model of discovery.
"They were doing it purely out of curiosity, like Leonardo da Vinci" /5
The links to the computer, digital, coding parallel advances are striking. Everything from the Homebrew Computer Club, the Asilomar conferences (there has been one for #AI), patent fights over chips, 0|1 vs ACGT, and so much more /6
Isaacson does a wonderful job differentiating germline editing, such as the reckless #CRISPR Babies work by Jiankui, to the remarkable progress in somatic editing @davidrliu@skathire /7
For me, the most heartwarming part of the book was he how brought Doudna and Charpentier back together again.
The infamous @Zoom get together /8
I asked Walter about the importance of scientists playing a role in public policy, since that certainly was not Jennifer Doudna's background. His response is remarkably insightful (not shown here) /9
On the democratization of #CRISPR, Isaacson takes a bit of a contrarian view (from the life science community) in supporting the DIY work of @4LOVofScience /10
Both @cuttingforstone and I were so deeply impressed with how lucid he made such a complex topic & into a veritable page turner. I can't recommend it enough fo anyone wanting to learn more about this breakthrough— it will have transformative impact in medicine and science
• • •
Missing some Tweet in this thread? You can try to
force a refresh
New @NEJM
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated
In other GLP-1 new publications today
—Country-wide Sweden reduced hospitalizations for alcohol or substance abuse with these drugs jamanetwork.com/journals/jamap… @JAMAPsych
—Concerns about discontinuation jamanetwork.com/journals/jama/… @JAMA_current
Other new anti-obesity drugs in the pipeline, one that also increases energy expenditure
@NatureNV nature.com/articles/d4158…
A dedicated issue of @ScienceTM on #LongCovid
—Sex-specific differences, with perspective by @VirusesImmunity and @SilvaJ_C
—Insights for therapies @AndreaCoxMDPhD
—Deconvoluting "Osler's Web" @MichaelPelusoMD @DeeksSteven @DrMaureenHanson @SaydahSharon
—+RECOVER Trial, Lyme disease
An elegant @Nature study by @AkassoglouLab has illuminated our understanding of the role of fibrin (component of blood clots), #SARSCoV2, and brain inflammation in Covid and #LongCovid.
This discovery and more in the new Ground Truths podcast, with transcript, key figures (such as as the one below) and citations. Open-access. Link in my profile.
A clip from our conversation. Unknowingly, @AkassoglouLab was gearing up for understanding this complex pathophysiology for many years before Covid hit
For treatment, it's not just as simple as preventing fibrin clots. It's isolating the pro-inflammatory action of fibrin, targeted by the antibody
Covid and increased risk of major adverse cardiovascular events (MACE) 3-years out
2-fold increased for any severity of Covid
~4-fold increase for Covid requiring hospitalization
"a coronary artery disease equivalent"
interaction with non-O blood types
@uk_biobankahajournals.org/doi/10.1161/AT…
"A major finding from our analyses was that the risk
of MACE among the subset of hospitalized COVID-
19 cases without known CVD (ie, primary prevention
patients) was comparable to (or even slightly higher than) the risk in patients with CVD, PAD, or diabetes but without COVID-19."
"one of the first examples of a gene-pathogen exposure interaction for thrombotic events"
I think it's the first one documented, likely others to be unraveled
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…